Laura Biganzoli

Summary

Country: Italy

Publications

  1. doi Taxanes in the treatment of breast cancer: Have we better defined their role in older patients? A position paper from a SIOG Task Force
    L Biganzoli
    Nuovo Ospedale Santo Stefano Istituto Toscano Tumori, Prato, Italy Electronic address
    Cancer Treat Rev 43:19-26. 2016
  2. doi Oral single-agent chemotherapy in older patients with solid tumours: A position paper from the International Society of Geriatric Oncology (SIOG)
    L Biganzoli
    Medical Oncology Department, New Prato Hospital, Istituto Toscano Tumori, via Suor Niccolina Infermiera, 20, 59100 Prato, Italy Electronic address
    Eur J Cancer 51:2491-500. 2015
  3. doi Evaluation of the cardiovascular health study (CHS) instrument and the Vulnerable Elders Survey-13 (VES-13) in elderly cancer patients. Are we still missing the right screening tool?
    L Biganzoli
    Sandro Pitigliani Medical Oncology Unit, Department of Oncology, Hospital of Prato, Istituto Toscano Tumori, Prato, Italy
    Ann Oncol 24:494-500. 2013
  4. doi Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA)
    Laura Biganzoli
    Sandro Pitigliani Medical Oncology Unit, Istituto Toscano Tumori, Hospital of Prato, Prato, Italy
    Lancet Oncol 13:e148-60. 2012
  5. doi First-line bevacizumab-containing therapy for breast cancer: results in patients aged≥70 years treated in the ATHENA study
    L Biganzoli
    Sandro Pitigliani Medical Oncology Unit, Prato Hospital, Istituto Toscano Tumori, Prato, Italy
    Ann Oncol 23:111-8. 2012
  6. ncbi Clinical decision making in breast cancer: TAM and aromatase inhibitors for older patients -- a jungle?
    Laura Biganzoli
    Sandro Pitigliani Medical Oncology Unit, Hospital of Prato, Tuscany Cancer Institute, Piazza dell Ospedale, 59100 Prato, Italy
    Eur J Cancer 43:2270-8. 2007
  7. ncbi Adjuvant chemotherapy in elderly patients with breast cancer: a survey of the Breast International Group (BIG)
    L Biganzoli
    Jules Bordet Institute, Brussels, Belgium
    Ann Oncol 15:207-10. 2004
  8. ncbi Adjuvant therapy in elderly patients with breast cancer
    Laura Biganzoli
    Sandro Pitigliani Medical Oncology Unit, Hospital of Prato, Italy
    Clin Breast Cancer 5:188-95; discussion 196-7. 2004
  9. ncbi A joined analysis of two European Organization for the Research and Treatment of Cancer (EORTC) studies to evaluate the role of pegylated liposomal doxorubicin (Caelyx) in the treatment of elderly patients with metastatic breast cancer
    Laura Biganzoli
    Sandro Pitigliani Medical Oncology Unit, Department of Oncology, Hospital of Prato, Prato, Italy
    Crit Rev Oncol Hematol 61:84-9. 2007
  10. doi Taxanes in the elderly: can we gain as much and be less toxic?
    Laura Biganzoli
    Sandro Pitigliani Medical Oncology Unit, Department of Oncology, Hospital of Prato, Tuscany Cancer Institute, Piazza dell Ospedale 2, 59100 Prato, Italy
    Crit Rev Oncol Hematol 70:262-71. 2009

Detail Information

Publications49

  1. doi Taxanes in the treatment of breast cancer: Have we better defined their role in older patients? A position paper from a SIOG Task Force
    L Biganzoli
    Nuovo Ospedale Santo Stefano Istituto Toscano Tumori, Prato, Italy Electronic address
    Cancer Treat Rev 43:19-26. 2016
    ....
  2. doi Oral single-agent chemotherapy in older patients with solid tumours: A position paper from the International Society of Geriatric Oncology (SIOG)
    L Biganzoli
    Medical Oncology Department, New Prato Hospital, Istituto Toscano Tumori, via Suor Niccolina Infermiera, 20, 59100 Prato, Italy Electronic address
    Eur J Cancer 51:2491-500. 2015
    ..v. administration. For elderly cancer patients in general, metronomic chemotherapy combines good tolerability with acceptable activity. ..
  3. doi Evaluation of the cardiovascular health study (CHS) instrument and the Vulnerable Elders Survey-13 (VES-13) in elderly cancer patients. Are we still missing the right screening tool?
    L Biganzoli
    Sandro Pitigliani Medical Oncology Unit, Department of Oncology, Hospital of Prato, Istituto Toscano Tumori, Prato, Italy
    Ann Oncol 24:494-500. 2013
    ..This study evaluated the accuracy of the cardiovascular health study (CHS) instrument in predicting abnormality in CGA. The vulnerable elders' survey-13 (VES-13) was also evaluated...
  4. doi Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA)
    Laura Biganzoli
    Sandro Pitigliani Medical Oncology Unit, Istituto Toscano Tumori, Hospital of Prato, Prato, Italy
    Lancet Oncol 13:e148-60. 2012
    ..Recommendations were updated for screening, primary endocrine therapy, surgery, radiotherapy, neoadjuvant and adjuvant systemic therapy, and metastatic breast cancer...
  5. doi First-line bevacizumab-containing therapy for breast cancer: results in patients aged≥70 years treated in the ATHENA study
    L Biganzoli
    Sandro Pitigliani Medical Oncology Unit, Prato Hospital, Istituto Toscano Tumori, Prato, Italy
    Ann Oncol 23:111-8. 2012
    ..To gain information on first-line bevacizumab combined with chemotherapy in the elderly, we analyzed data from the ATHENA trial in routine oncology practice...
  6. ncbi Clinical decision making in breast cancer: TAM and aromatase inhibitors for older patients -- a jungle?
    Laura Biganzoli
    Sandro Pitigliani Medical Oncology Unit, Hospital of Prato, Tuscany Cancer Institute, Piazza dell Ospedale, 59100 Prato, Italy
    Eur J Cancer 43:2270-8. 2007
    ..Longer follow-up of already published trials and additional data coming from ongoing studies will better define when and how to use AIs in the adjuvant setting...
  7. ncbi Adjuvant chemotherapy in elderly patients with breast cancer: a survey of the Breast International Group (BIG)
    L Biganzoli
    Jules Bordet Institute, Brussels, Belgium
    Ann Oncol 15:207-10. 2004
    ..To collect oncologists' experience and opinion on adjuvant chemotherapy in elderly breast cancer patients...
  8. ncbi Adjuvant therapy in elderly patients with breast cancer
    Laura Biganzoli
    Sandro Pitigliani Medical Oncology Unit, Hospital of Prato, Italy
    Clin Breast Cancer 5:188-95; discussion 196-7. 2004
    ..Therefore, specific clinical trials are needed to investigate adjuvant treatments tailored for the heterogeneous older population...
  9. ncbi A joined analysis of two European Organization for the Research and Treatment of Cancer (EORTC) studies to evaluate the role of pegylated liposomal doxorubicin (Caelyx) in the treatment of elderly patients with metastatic breast cancer
    Laura Biganzoli
    Sandro Pitigliani Medical Oncology Unit, Department of Oncology, Hospital of Prato, Prato, Italy
    Crit Rev Oncol Hematol 61:84-9. 2007
    ..The higher therapeutic index of Caelyx 50 mg/m(2) every 4 weeks makes it, of the two dose schedules investigated, the preferred regimen in the elderly...
  10. doi Taxanes in the elderly: can we gain as much and be less toxic?
    Laura Biganzoli
    Sandro Pitigliani Medical Oncology Unit, Department of Oncology, Hospital of Prato, Tuscany Cancer Institute, Piazza dell Ospedale 2, 59100 Prato, Italy
    Crit Rev Oncol Hematol 70:262-71. 2009
    ..e. docetaxel and paclitaxel in elderly patients with the aim to increase their therapeutic index. In addition, recent data on the role of nanoparticle albumine-bound paclitaxel in breast cancer are discussed in this paper...
  11. doi The continued evidence from overviews: what is the clinical utility?
    Natalie Turner
    Sandro Pitigliani Medical Oncology Unit, Department of Oncology, Hospital of Prato, Istituto Toscano Tumori, Prato, Italy
    Breast 22:S8-11. 2013
    ..With these considerations, the Overview has become less clinically relevant as a tool for guiding adjuvant chemotherapy treatment decisions, and a new direction is required. ..
  12. doi Adjuvant chemotherapy--the dark side of clinical trials. Have we learnt more?
    Catherine Oakman
    Sandro Pitigliani Medical Oncology Unit, Department of Oncology, Hospital of Prato, Tuscany Cancer Institute, Prato, Italy
    Breast 18:S18-24. 2009
    ..The basal phenotype may be predictive of benefit from DNA damaging agents...
  13. doi Adjuvant systemic treatment for individual patients with triple negative breast cancer
    Catherine Oakman
    Sandro Pitigliani Medical Oncology Unit, Department of Oncology, Hospital ofPrato, Istituto Toscano Tumori, Piazza Ospedale 2, 59100 Prato, Italy
    Breast 20:S135-41. 2011
    ..This review will focus on systemic chemotherapy in early TNBC, particularly anthracyclines and platinums, and potential predictive tools to guide chemotherapy use...
  14. doi Inter- and intra-tumoral heterogeneity in DNA damage evaluated by comet assay in early breast cancer patients
    Francesca Galardi
    Translational Research Unit, Department of Oncology, Hospital of Prato, Istituto Toscano Tumori, Prato, Italy
    Breast 21:336-42. 2012
    ..Comet assay warrants further study as a potential clinical tool for identification of tumoral DNA damage and ultimately, individualised use of DNA damaging therapy...
  15. doi Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer
    Valentina Guarneri
    Department of Oncology, Hematology and Respiratory Diseases, University of Modena and Reggio Emilia, University Hospital, Via del Pozzo 71, 41100 Modena, Italy
    Breast Cancer Res Treat 122:181-8. 2010
    ..Good oral hygiene, dental examination, and avoidance of invasive dental procedures remain important in patients receiving bisphosphonates, irrespective of bevacizumab administration...
  16. doi Topoisomerase II alpha as a marker predicting anthracyclines' activity in early breast cancer patients: ready for the primetime?
    Angelo Di Leo
    Sandro Pitigliani Medical Oncology Unit, Department of Oncology, Hospital of Prato, Istituto Toscano Tumori, Prato, Italy
    Eur J Cancer 44:2791-8. 2008
    ..This manuscript reviews and discusses results from randomised clinical studies evaluating topoisomerase II alpha (topo II) as a marker predicting anthracyclines' activity in early breast cancer patients...
  17. doi Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients
    Marta Pestrin
    Translational Research Unit c o Department of Oncology, Hospital of Prato, Istituto Toscano Tumori, Piazza dell Ospedale 2, 59100, Prato, Italy
    Breast Cancer Res Treat 118:523-30. 2009
    ..278). Our study suggests that a subset of patients with HER2-negative primary tumors develops HER2-positive CTCs during disease progression...
  18. ncbi Chemotherapy for metastatic breast cancer
    Laura Biganzoli
    Sandro Pitigliani Medical Oncology Unit, Department of Oncology, Prato Hospital, Prato, Italy
    Curr Opin Obstet Gynecol 16:37-41. 2004
    ..This review is intended to summarize the most up-to-date information in the field of chemotherapy for advanced breast cancer...
  19. ncbi Elderly breast cancer patients: adjuvant chemotherapy and adjuvant endocrine therapy
    Laura Biganzoli
    Medical Oncology Unit, Department of Oncology, Hospital of Prato, Prato, Italy
    Gynakol Geburtshilfliche Rundsch 45:137-42. 2005
    ..Specific clinical trials are therefore needed to investigate adjuvant treatments tailored for the heterogeneous older population...
  20. ncbi Using specific cytotoxics with a targeted mind
    Angelo Di Leo
    Sandro Pitigliani Medical Oncology Unit, Department of Oncology, Hospital of Prato, Tuscany Cancer Institute, Prato, Italy
    Breast 16:S120-6. 2007
    ..This "targeted" approach to chemotherapy might ultimately lead to a more effective strategy in breast cancer medical treatment...
  21. ncbi Randomized, controlled trial investigating short-term health-related quality of life with doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: European Organization for Re
    Andrew Bottomley
    Quality of Life Unit, European Organization for Research and Treatment of Cancer Data Center, Insitut Jules Bordet, Brussels, Belgium
    J Clin Oncol 22:2576-86. 2004
    ..To compare health-related quality of life (HRQOL) in patients with metastatic breast cancer receiving the combination of doxorubicin and paclitaxel (AT) or doxorubicin and cyclophosphamide (AC) as first-line chemotherapy treatment...
  22. pmc Recent advances in systemic therapy: new diagnostics and biological predictors of outcome in early breast cancer
    Catherine Oakman
    Sandro Pitigliani Medical Oncology Unit, Hospital of Prato, Istituto Toscano Tumori, Prato, Italy
    Breast Cancer Res 11:205. 2009
    ..Extensive research continues on predictive gene identification for specific chemotherapeutic agents, particularly the anthracyclines, taxanes and alkylating agents...
  23. ncbi Moving forward with capecitabine: a glimpse of the future
    Laura Biganzoli
    EORTC Investigational Drug Branch for Breast Cancer, Chemotherapy Unit, Institut Jules Bordet, Brussels, Belgium
    Oncologist 7:29-35. 2002
    ..Confirmatory studies for many of these combinations and phase III trials versus standard therapy are now warranted...
  24. ncbi Metabolomics: available results, current research projects in breast cancer, and future applications
    Wederson Marcos Claudino
    Sandro Pitigliani Medical Oncology Unit, Hospital of Prato, Prato, Italy
    J Clin Oncol 25:2840-6. 2007
    ..In the last section, research projects ongoing at our institution and future challenges for metabolomics will be presented and briefly discussed...
  25. ncbi Selection of chemotherapeutic drugs in adjuvant programs based on molecular profiles: where do we stand?
    Laura Biganzoli
    Sandro Pitigliani Medical Oncology Unit, Department of Oncology, Hospital of Prato, Piazza dell Ospedale 2, 59100 Prato, Italy
    Crit Rev Oncol Hematol 62:1-8. 2007
    ....
  26. ncbi Doxorubicin-paclitaxel: a safe regimen in terms of cardiac toxicity in metastatic breast carcinoma patients. Results from a European Organization for Research and Treatment of Cancer multicenter trial
    Laura Biganzoli
    IDBBC Unit, EORTC IDBBC, Jules Bordet Institute, Boulevard de Waterloo 121, 7th Floor, 1000 Brussels, Belgium
    Cancer 97:40-5. 2003
    ..The potential cardiotoxicity of the doxorubicin-paclitaxel regimen, when paclitaxel is given shortly after the end of the anthracycline infusion, is an issue of concern, as suggested by small single institution Phase II studies...
  27. doi Breast cancer in the elderly: which lessons have we learned?
    Natalie Turner
    Sandro Pitigliani Medical Oncology Unit, Department of Oncology, Hospital of Prato, Istituto Toscano Tumori, Piazza dell Ospedale 2, Prato, Italy
    Future Oncol 9:1871-81. 2013
    ..Future advances should incorporate more accurate and efficient means for determining the biological age of elderly breast cancer patients, which will better define the risk:benefit ratio of adjuvant chemotherapy...
  28. doi Defining optimal duration and predicting benefit from chemotherapy in patients with luminal-like subtypes
    Christopher D Hart
    Sandro Pitigliani Medical Oncology Department, Hospital of Prato, Istituto Toscano Tumori, Prato, Italy
    Breast 24:S136-42. 2015
    ....
  29. ncbi Predictive molecular markers in the adjuvant therapy of breast cancer: state of the art in the year 2002
    Angelo Di Leo
    Department of Chemotherapy, Jules Bordet Institute, Brussels, Rue Heger Bordet 1, 1000 Brussels, Belgium
    Int J Clin Oncol 7:245-53. 2002
    ..In the last part of the article, the most important findings have been summarized and future avenues of research have been outlined...
  30. doi Uncovering the metabolomic fingerprint of breast cancer
    Catherine Oakman
    Department of Oncology, Hospital of Prato, Istituto Toscano Tumori, Prato, Italy
    Int J Biochem Cell Biol 43:1010-20. 2011
    ..The dominant metabolic pathways and metabolite disturbances associated with malignant transformation of breast cells will be outlined, leading to an overview of potential clinical implications for individuals with breast cancer...
  31. doi New strategies to identify molecular markers predicting chemotherapy activity and toxicity in breast cancer
    A Di Leo
    Sandro Pitigliani Medical Oncology Unit, Hospital of Prato, Istituto Toscano Tumori, Prato, Italy
    Ann Oncol 18:xii8-14. 2007
    ..Ongoing studies should help to answer important questions relating to the use of metabolomics and CTC evaluation as new strategies to monitor cancer progression and identify markers of chemotherapy activity and toxicity...
  32. doi Challenges in the management of advanced, ER-positive, HER2-negative breast cancer
    Christopher D Hart
    Sandro Pitigliani Medical Oncology Unit, Hospital of Prato, Instituto Toscano Tumori, Via Suor Niccolina 20, Prato, PO 59100, Italy
    Nat Rev Clin Oncol 12:541-52. 2015
    ....
  33. doi Adjuvant chemotherapy: which patient? What regimen?
    Natalie Turner
    From the Sandro Pitigliani Medical Oncology Department, Hospital of Prato, Istituto Toscano Tumori, Prato, Italy Translational Research Unit, Department of Medical Oncology, Hospital of Prato, Istituto Toscano Tumori, Prato, Italy
    Am Soc Clin Oncol Educ Book 33:3-8. 2013
    ..For this, consideration must be given to the combination of underlying tumor biology, tumor stage, and patient characteristics, such as age and tolerability of side effects. ..
  34. doi Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study
    Marta Pestrin
    Medical Oncology Unit, Hospital of Prato, Prato, Italy
    Breast Cancer Res Treat 134:283-9. 2012
    ..However, considering that only 1/139 screened patients may potentially have derived benefit from this approach, future trials designed according to the presented strategy cannot be recommended...
  35. ncbi An EORTC-IDBBC phase I study of gemcitabine and continuous infusion 5-fluorouracil in patients with metastatic breast cancer resistant to anthracyclines or pre-treated with both anthracyclines and taxanes
    A Awada
    Jules Bordet Institute, Chemotherapy Unit, Bd de Waterloo 125, 1000 Brussels, Belgium
    Eur J Cancer 38:773-8. 2002
    ....
  36. doi Serum Metabolomic Profiles Identify ER-Positive Early Breast Cancer Patients at Increased Risk of Disease Recurrence in a Multicenter Population
    Christopher D Hart
    Sandro Pitigliani Medical Oncology Department, Hospital of Prato, Istituto Toscano Tumori, Prato, Italy
    Clin Cancer Res . 2017
    ..Here, we investigated this further using preoperative serum samples from ER-positive, premenopausal women with EBC who were enrolled in an international phase III trial...
  37. doi Continued value of adjuvant anthracyclines as treatment for early breast cancer
    Natalie Turner
    Sandro Pitigliani Medical Oncology Department, Prato Hospital, Istituto Toscano Tumori, Prato, Italy
    Lancet Oncol 16:e362-9. 2015
    ..The risks remain substantially outweighed by the benefits of treatment with anthracyclines, and thus, they maintain an important role in adjuvant treatment of breast cancer, particularly in women with high-risk disease...
  38. ncbi Neulasta (pegfilgrastim): a once-per-cycle option for the management of chemotherapy-induced neutropenia
    Laura Biganzoli
    Sandro Pitigliani Medical Oncology Unit, Department of Oncology, Prato Hospital, Italy
    Semin Oncol 31:27-34. 2004
    ..In addition to prevention of chemotherapy-induced neutropenia in 21- and 28-day regimens, future studies are examining the suitability of pegfilgrastim in dose-dense therapy and other cancer settings...
  39. ncbi Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial
    L Biganzoli
    Investigational Drug Branch for Breast Cancer, European Organization for the Research and Treatment of Cancer Data Center, and Jules Bordet Institute, Brussels, Belgium
    J Clin Oncol 20:3114-21. 2002
    ..To compare the efficacy and tolerability of the combination of doxorubicin and paclitaxel (AT) with a standard doxorubicin and cyclophosphamide (AC) regimen as first-line chemotherapy for metastatic breast cancer...
  40. ncbi Adjuvant chemotherapy in the elderly
    L Biganzoli
    Jules Bordet Institute, Chemotherapy Unit, Brussels, Belgium
    Ann Oncol 14:iii1-3. 2003
  41. ncbi The impact of chemotherapy dose density and dose intensity on breast cancer outcome: what have we learned?
    M J Piccart
    Chemotherapy Unit, Department of Internal Medicine, Institut Jules Bordet, Association Hospitalière de Bruxelles, Centre des Tumeurs de l ULB, 1 rue Héger Bordet, B 1000, Brussels, Belgium
    Eur J Cancer 36:S4-10. 2000
    ..These results represent our current state of knowledge, but clinical trials are being performed to evaluate further the effect of dose intensity, dose density and cumulative dose of key therapeutic agents on patient outcomes...
  42. ncbi Controversies in the adjuvant treatment of breast cancer: the role of taxanes
    A Di Leo
    Sandro Pitigliani Medical Oncology Unit, Department of Oncology, Hospital of Prato, Prato Tuscany, Italy
    Ann Oncol 15:iv17-21. 2004
  43. ncbi EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx, Doxil) at a 6-week interval in patients with metastatic breast cancer. European Organization for Research and Treatment of Cancer
    A Hamilton
    IDBBC, Brussels, Belgium
    Ann Oncol 13:910-8. 2002
    ....
  44. ncbi The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamo
    G Atalay
    Jules Bordet Institute, Brussels, Belgium
    Ann Oncol 15:211-7. 2004
    ..This study, as a companion substudy of an EORTC phase II trial (10951), evaluated the impact of exemestane, a steroidal aromatase inactivator, on the lipid profile of postmenopausal metastatic breast cancer (MBC) patients...
  45. ncbi Adjuvant therapy in the elderly: making the right decision
    Hyman B Muss
    University of Vermont and Vermont Cancer Center, Burlington, VT 05401, USA
    J Clin Oncol 25:1870-5. 2007
    ..In addition, we discuss the role of comorbidity and how it factors in treatment decisions. Finally, we discuss future research directions and funding for elders with cancer...
  46. ncbi Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology
    Hans Wildiers
    Department of General Medical Oncology, University Hospital Gasthuisberg, Leuven, Belgium
    Lancet Oncol 8:1101-15. 2007
    ..The available evidence was reviewed and synthesised to provide consensus recommendations regarding the care of breast cancer in older adults...
  47. doi Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer
    Martine J Piccart-Gebhart
    Institut Jules Bordet, 121 Boulevard de Waterloo, 1000 Brussels, Belgium
    J Clin Oncol 26:1980-6. 2008
    ..This meta-analysis uses data from all relevant trials to detect any advantages of taxanes in terms of tumor response, progression-free survival (PFS), and survival...
  48. doi Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer
    Tomasz Burzykowski
    Hasselt University, Center for Statistics, Agoralaan, Bldg D, 3590 Diepenbeek, Belgium
    J Clin Oncol 26:1987-92. 2008
    ....
  49. ncbi What is the effect of systemic anticancer treatment on cognitive function?
    Alessandro Minisini
    Unit of Medical Oncology, University of Udine, Italy
    Lancet Oncol 5:273-82. 2004
    ..These trials should have sufficient statistical power and, importantly, should also be prospective...